Long-term Anticoagulation in a Patient With Severe Hemophilia A (HAAC)

December 31, 2025 updated by: University Hospital, Strasbourg, France

Report of a Clinical-biological Case: "Long-term Anticoagulation in a Patient With Severe Hemophilia A

To date, and to our knowledge, no case of severe hemophilia A patients receiving long-term anticoagulation has been published. Severe hemophilia A is a hereditary bleeding disorder characterized by a factor VIII (FVIII) deficiency of <1%. Anticoagulation remains a real challenge in these patients, given the precarious hemostatic balance between the bleeding risk associated with anticoagulation and the antithrombotic protection associated with factor VIII deficiency. The advent of new replacement therapies, characterized by FVIII molecules with a prolonged or very prolonged half-life, provides a high level of FVIII coverage (and therefore protection against the risk of bleeding) in patients receiving prophylaxis, thus facilitating the initiation of anticoagulation therapy.

Study Overview

Status

Recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • France
      • Strasbourg, France, 67091
        • Recruiting
        • Laboratoire d'Hématologie - Unité d'Hémostase - CHU de Strasbourg - France
        • Sub-Investigator:
          • Dominique DESPREZ, MD
        • Contact:
        • Principal Investigator:
          • Laurent SATTLER, PharmD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Adult patient (≥ 18 years) with severe hemophilia A

Description

Inclusion Criteria:

  • Adult patient (≥ 18 years) with severe hemophilia A
  • Absence of written objection in the subject's medical record to the reuse of their data for scientific research purposes.

Exclusion Criteria:

- Subject having expressed objection to the reuse of their data for scientific research

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
FVIII Level
Time Frame: Up to 15 months

Factor VIII (FVIII) is a clotting protein: it enables the blood to form a clot to stop bleeding.

Its level indicates how well the blood clots, which is useful for diagnosing or monitoring hemophilia A before surgery.

General values:

  • Normal: approximately 50 to 150%
  • Too low: risk of bleeding
  • Too high: may increase the risk of clots
Up to 15 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Strasbourg, France

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 22, 2025

Primary Completion (Estimated)

January 1, 2026

Study Completion (Estimated)

January 31, 2026

Study Registration Dates

First Submitted

September 22, 2025

First Submitted That Met QC Criteria

December 31, 2025

First Posted (Estimated)

January 2, 2026

Study Record Updates

Last Update Posted (Estimated)

January 2, 2026

Last Update Submitted That Met QC Criteria

December 31, 2025

Last Verified

September 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 9816 (Other Identifier: Fred Hutch/University of Washington Cancer Consortium)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hemophilia A

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tanzania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe